nach oben

Clinical Research in Cardiology

Erschienen in:

22.03.2017 | Review

Hypertension up to date: SPRINT to SPYRAL

verfasst von: Saarraaken Kulenthiran, Sebastian Ewen, Michael Böhm, Felix Mahfoud

Erschienen in: Clinical Research in Cardiology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is the most common chronic cardiovascular condition with increasing prevalence all over the world. Treatment of patients at risk requires a multimodal therapeutic concept to adjust blood pressure, including systematic identification of secondary causes of hypertension or pseudo-resistance, lifestyle modification, polypharmacy, and as well as accompanying risk factors and comorbidities. The present review discusses recent studies on patients with increased cardiovascular risk potentially influencing future treatment strategies. It covers blood pressure targets in patients at risk (SPRINT), novel treatment options such as angiotensin receptor neprilysin inhibitors, discusses the treatment of patients with impaired glucose tolerance, and appreciates novelties in controlling therapy-resistant hypertension by fourth-line pharmacotherapies (PATHWAY), as well as new interventional approaches.

Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Kc A, Kyu HH et al (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. doi:10.1016/S0140-6736(15)00128-2 PubMedCentral

Drazen JM, Morrissey S, Campion EW, Jarcho JA (2015) A SPRINT to the finish. N Engl J Med. doi:10.1056/NEJMe1513991

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.1093/eurheartj/eht151 CrossRefPubMed

Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575–1585. doi:10.1056/NEJMoa1001286 CrossRefPubMed

Lee M, Saver JL, Hong KS, Hao Q, Ovbiagele B (2012) Does achieving an intensive versus usual blood pressure level prevent stroke? Ann Neurol 71(1):133–140. doi:10.1002/ana.22496 CrossRefPubMed

SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382(9891):507–515. doi:10.1016/S0140-6736(13)60852-1

Upadhyay A, Earley A, Haynes SM, Uhlig K (2011) Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154(8):541–548. doi:10.7326/0003-4819-154-8-201104190-00335 CrossRefPubMed

Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, Salvi P, Zamboni M, Manckoundia P, Hanon O, Gautier S et al (2015) Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med 175(6):989–995CrossRefPubMed

Mossello E, Pieraccioli M, Nesti N (2015) Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med 175(4):578–585CrossRefPubMed

10.

Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. doi:10.1056/NEJMoa1511939

11.

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387:435–443CrossRefPubMed

12.

Perkovic V, Rodgers A (2015) Redefining Blood-Pressure Targets - SPRINT Starts the Marathon. N Engl J Med. doi:10.1056/NEJMe1513301 PubMed

13.

Thomopoulos C, Parati G, Zanchetti A (2014) Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 32:2285–2295CrossRefPubMed

14.

Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerours? Ann Intern Med 144:884–893CrossRefPubMed

15.

Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PC et al (2016) Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet S0140-6736(16):31326–31325. doi:10.1016/S0140-6736(16)31326-5.

16.

Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37(6):1721–1728. doi:10.2337/dc13-2334 CrossRefPubMedPubMedCentral

17.

Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42(5):1489–1494. doi:10.1161/STROKEAHA.110.602615 CrossRefPubMed

18.

Meyers MG, Godwin M, Daves M, Kiss A, Tobe SW, Kaczorowski J (2010) Meausurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55:195–200CrossRef

19.

Filipovsky J, Seidlerova J, Kratochvil Z, Karnosova P, Hronova M, Mayer O Jr. (2016) Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press. doi:10.3109/08037051.2015.1134086 PubMed

20.

Lonn EN, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Yusuf S (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009–2020CrossRefPubMed

21.

Packer M (1995) Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 16(Suppl F):4–6. doi:10.1093/eurheartj/16.suppl_F.4.CrossRefPubMed

22.

Ruilope LM, Dukat A, Böhm M, Lacourciere Y, Gong J, Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. The Lancet 375(9722):1255–1266. doi:10.1016/S0140-6736(09)61966-8 CrossRef

23.

Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10(7):607–613CrossRefPubMed

24.

Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 17(2):103–111. doi:10.1016/j.amjhyper.2003.09.014 CrossRefPubMed

25.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. doi:10.1056/NEJMoa1409077 CrossRefPubMed

26.

Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 16(6):671–677. doi:10.1002/ejhf.76 CrossRefPubMed

27.

Catala-Lopez F, Macias Saint-Gerons D, de la Fuente Honrubia C, Martin-Serrano G (2014) Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies. Rev Esp Salud Publica 88(1):37–65.CrossRefPubMed

28.

Gaziano TA, Fonarow GC, Claggett B et al (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 1(6):666–672CrossRefPubMed

29.

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM, ATMOSPHERE Committees Investigators (2016) Aliskiren, enalapril or aliskiren and enalapril in heart failure. N Engl J Med 374(16):1521–1532CrossRefPubMed

30.

Williams B, Cockcroft JR, Kario K, Zappe DH, Cardenas P, Hester A, Brunel P, Zhang J (2014) Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 4(2):e004254. doi:10.1136/bmjopen-2013-004254 CrossRefPubMedPubMedCentral

31.

Williams B, Cockcroft JR, Kario K, Zappe DH, Wang Q, Guo W (2015) Principal results of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin Receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) Study. ESC Congress 2015; (London) oral presentation, 31 Aug 2015

32.

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557):201–207. doi:10.1016/S0140-6736(07)60108-1 CrossRefPubMed

33.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM, British Hypertension Society’s P, Treatment of Hypertension with Algorithm-based Therapy Studies G (2015) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. doi:10.1016/S2213-8587(15)00377-0

34.

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2224–2260. doi:10.1016/S0140-6736(12)61766-8 CrossRefPubMedPubMedCentral

35.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ (2015) Prevention and treatment of hypertension with algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open 5(8):e008951. doi:10.1136/bmjopen-2015-008951.CrossRefPubMedPubMedCentral

36.

Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M (2011) Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57(6):1069–1075. doi:10.1161/HYPERTENSIONAHA.111.169961 CrossRefPubMed

37.

Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA (2013) Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 31(10):2094–2102. doi:10.1097/HJH.0b013e3283638b1a CrossRefPubMed

38.

DiBona GF (2005) Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289(3):R633–R641. doi:10.1152/ajpregu.00258.2005 CrossRefPubMed

39.

Ewen S, Ukena C, Böhm M, Mahfoud F (2013) Percutaneous renal denervation: new treatment option for resistant hypertension and more? Heart 99(15):1129–1134. doi:10.1136/heartjnl-2012-301725 CrossRefPubMed

40.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401. doi:10.1056/NEJMoa1402670 CrossRefPubMed

41.

Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G, Investigators GSR (2015) First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 65(4):766–774. doi:10.1161/HYPERTENSIONAHA.114.05010 CrossRefPubMed

42.

Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104(12):1097–1105CrossRefPubMed

43.

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S et al (2015) Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36(4):219–227. doi:10.1093/eurheartj/ehu441 CrossRefPubMed

44.

Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, Bednar F, Zelinka T, Holaj R, Strauch B, Somloova Z, Taborsky M, Vaclavik J, Kocianova E, Branny M et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 65(2):407–413. doi:10.1161/HYPERTENSIONAHA.114.04019 CrossRefPubMed

45.

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand P-Y, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin P-F et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. The Lancet 385:1957–1965. doi:10.1016/s0140-6736(14)61942-5 CrossRef

46.

Pöss J, Ewen S, Schmieder RE, Muhler S, Vonend O, Ott C, Linz D, Geisel J, Rump LC, Schlaich M, Böhm M, Mahfoud F (2015) Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol 104(8):672–678CrossRefPubMed

47.

Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, Townsend R, Weber MA, Böhm M (2015) The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. doi:10.1016/j.ahj.2015.08.021 PubMed

48.

Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Bohm M, Melder RJ (2015) Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 66(16):1766–1775. doi:10.1016/j.jacc.2015.08.018 CrossRefPubMed

49.

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE et al (2015) Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 36(33):2219–2227. doi:10.1093/eurheartj/ehv192 CrossRefPubMed

50.

Spiering W, Van der Heyden J, Kroon AA, van der Meiracker AH, Devireddy C, Foster MT, Ghali MG, Mendelsohn FO, Reuter H, Bates MC et al (2016) Controlling and lowering blood pressure with the MobiusHD device: first-in-man interim results (CALM-FIM-Study). J Hypertens 2016(Suppl 2):e105. doi:10.1097/01.hjh.0000491608.58838.2e CrossRef

Titel: Hypertension up to date: SPRINT to SPYRAL
verfasst von: Saarraaken Kulenthiran
Sebastian Ewen
Michael Böhm
Felix Mahfoud
Publikationsdatum: 22.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 7/2017
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-017-1095-0

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Novel CMR techniques enable detection of even mild autoimmune myocarditis in a patient with systemic lupus erythematosus

Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction

Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent

Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpoints